Protagonist Therapeutics, Inc. (PTGX) - Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Protagonist Therapeutics is a biopharmaceutical company focused on peptide therapeutics for inflammatory/immunomodulatory diseases and hematology/blood disorders. The company has no commercialized products; revenue is derived from collaboration agreements with Johnson & Johnson (JNJ) regarding icotrokinra and Takeda regarding rusfertide.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $28.3 million | $255.0 million |
| Net Loss | $(11.7) million | $207.3 million (Income) |
| Operating Expenses | $47.6 million | $48.6 million |
| Operating Loss | $(19.3) million | $206.3 million (Income) |
| Cash & Marketable Securities | $697.9 million | $559.2 million |
| Operating Cash Flow | $125.4 million | $(27.4) million |
| Accumulated Deficit | $(352.2) million | $(340.5) million |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 89% year-over-year. Q1 2024 included a one-time $254.1 million recognition of the Takeda upfront payment. Q1 2025 revenue consisted of $22.8 million from a Takeda milestone (deemed probable) and $5.5 million from development services.
- Net Loss vs. Income: The company reported a net loss of $11.7 million compared to net income of $207.3 million in the prior year, primarily due to the absence of the large upfront revenue recognition in 2024.
- Operating Cash Flow Surge: Operating cash flow turned positive at $125.4 million, driven by the receipt of a $165.0 million milestone payment from JNJ in January 2025.
- Expense Trends: R&D expenses increased 6% to $35.9 million due to pre-clinical discovery costs (PN-881), while G&A expenses decreased 21% to $11.7 million due to lower one-time legal fees compared to Q1 2024.
Outlook, Commentary, and Risks
- Clinical Progress:
- Rusfertide: Positive topline data announced for the Phase 3 VERIFY trial in polycythemia vera (PV). A $25.0 million milestone was deemed probable. NDA filing is expected in Q4 2025.
- Icotrokinra: Positive Phase 3 data in plaque psoriasis (ICONIC-LEAD) and ulcerative colitis (ANTHEM-UC). JNJ is initiating a head-to-head trial against ustekinumab.
- Liquidity: Management expects existing cash and marketable securities ($697.9 million) to fund operations for at least the next 12 months.
- Revenue Outlook: Management expects 2025 revenue to be substantially lower than 2024, consisting mainly of deferred revenue recognition and potential milestones.
- Risks:
- Regulatory Disruption: Potential impact of FDA workforce reductions and government shutdowns on review timelines.
- Macroeconomic Factors: Inflation, interest rates, and geopolitical instability affecting capital markets and clinical costs.
- Development Risk: No guarantee of regulatory approval or commercial success for product candidates.
Investor Verification Checklist
- Verify the timing and conditions for the receipt of the $25.0 million Takeda milestone payment (payable upon completion of the VERIFY clinical study report).
- Monitor the status of the NDA filing for rusfertide, currently targeted for Q4 2025.
- Assess the impact of potential FDA staffing disruptions on the review of upcoming regulatory submissions.
- Review the burn rate relative to the $697.9 million cash position to confirm the 12-month liquidity runway.
- Track the progress of the icotrokinra head-to-head trial against ustekinumab initiated by JNJ.